233276-35-2 Usage
Description
(1s,3s)-3-(benzyloxy)cyclobutan-1-ol is a chiral cyclobutanol derivative with the molecular formula C11H14O2. It features a benzyl ether functional group and is characterized by its (1s,3s) stereochemistry. The unique structure and chirality of this compound make it a promising candidate for applications in organic synthesis and pharmaceutical development, as well as an interesting target for chemical research and drug discovery efforts.
Uses
Used in Organic Synthesis:
(1s,3s)-3-(benzyloxy)cyclobutan-1-ol is used as a key intermediate in organic synthesis for the preparation of various complex organic molecules. Its benzyl ether group can be selectively removed or modified, allowing for the synthesis of a wide range of compounds with diverse functional groups and properties.
Used in Pharmaceutical Development:
(1s,3s)-3-(benzyloxy)cyclobutan-1-ol is used as a chiral building block in the development of pharmaceuticals. Its unique stereochemistry and functional groups can be utilized to create enantiomerically pure compounds with potential therapeutic applications. The chiral nature of this compound can be leveraged to design drugs with improved selectivity and reduced side effects.
Used in Chemical Research:
(1s,3s)-3-(benzyloxy)cyclobutan-1-ol serves as a valuable research tool in chemical studies. Its unique structure and chirality make it an interesting target for investigating various aspects of chemical reactivity, stereoselectivity, and mechanistic insights. Researchers can use this compound to explore new synthetic methodologies, catalysis, and reaction pathways.
Used in Drug Discovery:
(1s,3s)-3-(benzyloxy)cyclobutan-1-ol is employed as a starting material or scaffold in drug discovery efforts. Its chiral cyclobutanol core and benzyl ether group can be further functionalized to generate novel bioactive molecules with potential therapeutic properties. (1s,3s)-3-(benzyloxy)cyclobutan-1-ol can be used to identify new lead compounds and optimize their pharmacological profiles for various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 233276-35-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,3,3,2,7 and 6 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 233276-35:
(8*2)+(7*3)+(6*3)+(5*2)+(4*7)+(3*6)+(2*3)+(1*5)=122
122 % 10 = 2
So 233276-35-2 is a valid CAS Registry Number.
233276-35-2Relevant articles and documents
TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
-
Paragraph 0452; 0453, (2021/02/12)
The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tan protein, such that tan protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tan. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tan protein. Diseases or disorders that result from aggregation or accumulation of tan protein are treated or prevented with compounds and compositions of the present disclosure.
6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS
-
Paragraph 0649-0650, (2021/11/13)
The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.
TYK2 INHIBITORS AND USES THEREOF
-
Paragraph 1337-1339; 1828-1830, (2020/05/14)
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
